<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000710387"><TermName>FOLFIRI-bevacizumab</TermName><TermPronunciation>(... beh-vuh-SIH-zoo-mab)</TermPronunciation><TermDefinition><DefinitionText>A chemotherapy combination used as an initial treatment of colorectal cancer that has spread. It includes the drugs leucovorin (folinic acid), fluorouracil, irinotecan hydrochloride, and bevacizumab. Also called FOLFIRI-Avastin regimen and FOLFIRI-bevacizumab regimen.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000733305" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;FOLFIRI-bevacizumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000733304" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;FOLFIRI-bevacizumab&quot;" language="es" id="_4"/><SpanishTermName>FOLFIRI-bevacizumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Régimen de quimioterapia combinada que se usa como terapia inicial del cáncer colorrectal. Incluye los medicamentos leucovorina (ácido folínico), fluorouracilo, clorhidrato de irinotecán y bevacizumab. También se llama régimen FOLFIRI-Avastin y régimen FOLFIRI-bevacizumab.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2011-08-24</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000698393">FOLFIRI-BEVACIZUMAB</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
